Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Summary

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.

Timeline

Start

2025-07-16

Primary completion

2027-11

Completion

2028-05

Drugs

Indications